Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer

Wei, Xiaoting1; Xu, Jianmin2,3; Zhong, Shuyuan2,3; Zou, Jinsen2,3; Cheng, Zhiqiang3,4; Ding, Zhiguang2,3; Zhou, Xuhui1

2022-07-01

10.1007/s00261-022-03592-4

Abdominal Radiology   影响因子和分区

2366-004X

2366-0058

["Purpose To investigate the diagnostic value of the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1) for clinically significant prostate cancer (CsPCa). We also aimed to combine PI-RADS v2.1 with prostate-specific antigen (PSA) derivatives to improve the predictive value of CsPCa.","Methods We retrospectively collected relevant data who underwent standard MRI examinations of the prostate and subjected to a prostate biopsy at Shenzhen People's hospital from November 2014 to November 2019. Included 125 cases of CsPCa and 383 cases of non-CsPCa. All cases were scored using the PI-RADS v2.1. The clinical data collected included age, PSA, free PSA/total PSA, prostate volume and PSA density (PSAD). A univariate analysis was performed to identify statistically significant indicators. Logistic regression was used to analyze the predictive value of the multi-parameter combination on CsPCa.","Results Except age, the difference in all of indicators between the CsPCa group and non-CsPCa group was statistically significant. The PI-RADS score and PSAD value had the highest diagnostic value. Logistic regression analysis revealed that the PI-RADS score and PSAD value were independent predictors of CsPCa, with a regression model AUC of 0.935. CsPCa detection rates were low when the PI-RADS score <= 2 or the PI-RADS score = 3 and the PSAD value <= 0.33 ng/ml/ml.","Conclusion Combining the PI-RADS score and PSAD value improved the predictive performance of CsPCa. Patients with a PI-RADS score <= 2 or a PI-RADS score = 3 and a PSAD value <= 0.33 ng/ml/ml can avoid an unnecessary biopsy."]

Prostate cancer Magnetic resonance imaging Biopsy Prostate-specific antigen

SCI

英语

其他

Radiology, Nuclear Medicine & Medical Imaging

Radiology, Nuclear Medicine & Medical Imaging

WOS:000821973300002

SPRINGER

Web of Science

1.Sun Yat Sen Univ, Affiliated Hosp 8, Dept Radiol, 3025 Sherman Middle Rd, Shenzhen 518036, Peoples R China
2.Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Radiol, Shenzhen 518020, Peoples R China
3.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen 518020, Peoples R China
4.Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Pathol, Shenzhen 518020, Peoples R China

Wei, Xiaoting,Xu, Jianmin,Zhong, Shuyuan,et al. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer[J]. Abdominal Radiology,2022.

Wei, Xiaoting.,Xu, Jianmin.,Zhong, Shuyuan.,Zou, Jinsen.,Cheng, Zhiqiang.,...&Zhou, Xuhui.(2022).Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.Abdominal Radiology.

Wei, Xiaoting,et al."Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer".Abdominal Radiology (2022).